Looking to build a 'dual sourcing' supply chain, WuXi Biologics shells out $183M for Bayer drug substance plant
Biologics have been particularly hot in 2020 with big drugmakers looking to bolster their portfolio — a trend that has been a serious boon for contract manufacturers. WuXi Biologics started off the year adding to its own production capacity in Germany to keep up with that expected demand, and now it’s going back to Deutschland for another expansion.
Shanghai-based Wuxi will drop roughly 150 million euros—or $183.3 million— in an acquisition deal for Bayer’s 330,000 square-foot drug substance facility in Wuppertal, Germany, as it seeks to enhance a supply network of Covid-19 vaccines and other biologics. The newest facility will also add to WuXi’s “global dual sourcing” strategy to add redundancy into its supply chain, CEO Chris Chen said in a release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.